An observational study in Inflammatory Bowel Diseases, sponsored by Yeouido St. Mary's Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-24.
Sponsored by Yeouido St. Mary's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of — 12 open to participants now, 15 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Korea, Republic of.
Among the 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of, this one is the 20th largest by enrollment of the 22 observational ones that give a count, is one of 6 that started in 2020, is one of 22 observational ones, and was the 42nd registered.
1,553 studies on the registry are indexed under Inflammatory Bowel Diseases; 424 are open to participants now.
Browse Inflammatory Bowel Diseases studies →12 of the 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Spyre Therapeutics, Inc. · Sites in Korea, Republic of, United States, Argentina and 33 more countries
Ages 18–75
Eli Lilly and Company · Sites in Korea, Republic of, United States, Austria and 13 more countries
Ages 2–17
Janssen Research & Development, LLC · Sites in Korea, Republic of, United States, Australia and 14 more countries
Ages 2–17
Chang Kyun Lee · Sites in Korea, Republic of
Ages 13–85
Takeda · Sites in Korea, Republic of
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 277 Inflammatory Bowel Diseases studies recruiting now, 134 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: Up to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 19 · Phase 4 2
First in 2007; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 236 across the 35 interventional studies, 240 across the 22 observational. Of the 35 that completed or were terminated, 18 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 57 have an industry lead sponsor. The 10 most frequent:
Yeouido St. Mary's Hospital is the lead sponsor of 4 studies on the registry; none are open to participants now.
Yeouido St. Mary's Hospital has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Inflammatory Bowel Diseases with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07166588Seoul National University HospitalResearch for the Precision Medicine in the Treatment of Inflammatory Bowel Disease | 2026-12-31 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT05428345TakedaA Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 57 studies in Inflammatory Bowel Diseases with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The aim of this study is to analyze gut microbiota in IBD patients.
Inflammatory bowel disease (IBD) (Crohn's disease (CD) and ulcerative colitis (UC)) occurs worldwide with differences in epidemiology, etiology, and phenotype between regions. Pathologically Inflammatory bowel disease (IBD) is in chronic complex inflammatory gut pathological condition. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The DNA of microbiota will be investigated with samples of stool, colon tissue. The aim is to establish a cohort group for IBD (1), to make a database on cohort group characteristics such as endoscopic findings, disease severity, epidemiology, and prognosis (2), to analyze gut flora in IBD patients (3).
All consecutive patients with IBD, presented to division of gastroenterology, Yeouido St.Mary's hospital, will be asked to participate in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The below 3 conditions must be met simultaneously.
Exclusion Criteria:
a patient meets any of the below conditions.
Number of participants with the remission of disease activity.
Disease activity is assessed in a clinical, endoscopic, and biochemical way. Each activity is determined by the Mayo score (in UC), Crohn's Disease Activity Index (in CD), Ulcerative Colitis Endoscopic Index of Severity (in UC), Simple Endoscopic Score for Crohn Disease (in CD), and biochemical findings (e.g. fecal calprotectin).
Time frame: through study completion, an average of 2 year
Plan to share: No
Ran from Oct 2020 to primary completion in Jun 2023, 32 months.
Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 132. This study's 32 months is below that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yeouido St. Mary's Hospital